RNA therapeutics company developing medicines to end the need for liver transplants using human liver data, AI discovery, and in-house RNA manufacturing.
Ochre Bio is developing RNA therapies for chronic liver diseases with significant fibrosis, aiming to eliminate the need for liver transplants for the 1.5 million people who die of liver disease globally each year. The company operates three integrated platforms: a Human Discovery Platform combining proprietary gene perturbation atlases with patient disease atlases to identify drug targets; a Human Validation Platform using perfused livers, diseased tissue slices, and primary cells with AI; and an in-house RNA Platform that shortens R&D cycle times from years to weeks. Teams are based in Oxford, Taipei, and New York City. Ochre Bio is a product of Ochre Bio.